NASDAQ:LTGO Latigo Biotherapeutics Q2 2026 Earnings Report $17.15 -0.61 (-3.43%) As of 09/25/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Latigo Biotherapeutics EPS ResultsActual EPS-$27.59Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALatigo Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALatigo Biotherapeutics Announcement DetailsQuarterQ2 2026Date9/3/2026TimeAfter Market ClosesConference Call DateThursday, September 3, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Latigo Biotherapeutics Earnings HeadlinesLatigo Biotherapeutics (NASDAQ:LTGO) Stock Rating Upgraded by Wall Street Zen4 hours ago | americanbankingnews.comLatigo Biotherapeutics Inc (LTGO)September 12, 2026 | investing.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now. | TradeSmith (Ad)Latigo Biotherapeutics Stock Price HistorySeptember 9, 2026 | investing.comLatigo Biotherapeutics Q2 Net Loss NarrowsSeptember 4, 2026 | finance.yahoo.comLatigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsSeptember 3, 2026 | globenewswire.comSee More Latigo Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Latigo Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Latigo Biotherapeutics and other key companies, straight to your email. Email Address About Latigo BiotherapeuticsLatigo Biotherapeutics (NASDAQ:LTGO) is a clinical-stage biopharmaceutical company developing non-opioid medicines for the treatment of acute and chronic pain. The company focuses on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of developing therapies that may provide pain relief without the risks associated with opioid medications. Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, led by LTG-001 for acute pain and additional research programs aimed at chronic pain conditions. The company is focused on advancing these candidates through clinical development and has not established a commercial product portfolio. Latigo was founded in 2021 with backing from life-sciences investors, including Third Rock Ventures. Its activities have been centered on research and clinical development in the United States. As a development-stage biotechnology company, its future operations depend on the results of clinical trials and regulatory review of its investigational therapies.View Latigo Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
